NYSE: VTRVentas Inc Stock
$61.65-0.48 (-0.77%)
Updated Dec 6, 2024
VTR Price
$61.65
Fair Value Price
N/A
Market Cap
$25.85B
52 Week Low
$41.45
52 Week High
$67.61
P/E
-385.31x
P/B
2.65x
P/S
5.52x
PEG
N/A
Dividend Yield
2.92%
Revenue
$4.80B
Earnings
-$66.50M
Gross Margin
42.6%
Operating Margin
11.46%
Profit Margin
-1.4%
Debt to Equity
1.56
Operating Cash Flow
$1B
Beta
1.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VTR Overview
Ventas Incorporated is a real estate investment trust (REIT) that owns and manages health care facilities in the U.S. and internationally.The company's portfolio of 1,200 properties includes nursing homes, medical office buildings, rehabilitation and acute care centres, special care centres, laboratories and research centres, and medical-surgical centres with a total value of $25B. The company was spun off from Vencor in 1998 and is headquartered in Chicago,IL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VTR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
C
Momentum
B
Sentiment
A
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Facility REIT
Industry Rating
D
VTR
Ranked#6 of 16
Ranked#6 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.83 | B | |
| $37.73 | B | |
| $39.25 | C |
Be the first to know about important VTR news, forecast changes, insider trades & much more!
VTR News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VTR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VTR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VTR is poor value based on its book value relative to its share price (2.65x), compared to the US REIT - Healthcare Facilities industry average (2.13x)
P/B vs Industry Valuation
VTR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more VTR due diligence checks available for Premium users.
Valuation
VTR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-385.31x
Industry
-12.81x
Market
29.86x
VTR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.65x
Industry
2.13x
VTR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VTR's financial health
Profit margin
Revenue
$1.2B
Net Income
$19.2M
Profit Margin
1.6%
VTR's Earnings (EBIT) of $550.44M... subscribe to Premium to read more.
Interest Coverage Financials
VTR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.3B
Liabilities
$15.2B
Debt to equity
1.56
VTR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VTR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$353.7M
Investing
-$429.5M
Financing
$624.4M
VTR's operating cash flow ($1.24B)... subscribe to Premium to read more.
Debt Coverage Financials
VTR vs Healthcare Facility REIT Stocks
Ventas Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.